Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Johnson and Johnson reveals “promising” results for ustekinumab

Johnson and Johnson reveals “promising” results for ustekinumab

29th February 2008

Johnson & Johnson (J&J) has revealed promising phase III study results for ustekinumab in the treatment of chronic plaque psoriasis.

One-year data from the phase III Phoenix trial showed that patients receiving ustekinumab every 12 weeks demonstrated sustained, clinically meaningful improvement in the treatment of moderate-to-severe plaque psoriasis through one year.

Findings, presented at the Annual Meeting of the American Academy of Dermatology, showed that 87 per cent of patients taking ustekinumab 45 mg and 91 per cent of subjects administered with ustekinumab 90 mg demonstrated at least a 75 per cent improvement as measured by the Psoriasis Area and Severity Index.

Kenneth Gordon, head of dermatology at Evanston Northwestern Healthcare in Illinois, US, suggested that ustekinumab could control plaque psoriasis with as little as four injections a year.

“We are encouraged by the results seen in clinical trials to date and the hope that ustekinumab may hold for patients and the dermatology community,” he added.

The study’s lead investigator Kim Papp described the results as “promising” which offered hope to patients who needed additional therapeutic options.

In December 2007, J&J subsidiary Janssen-Cilag announced that it had submitted a marketing authorisation application for ustekinumab to the European Medicines Agency.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.